DiGeorge syndrome critical region gene 6Genealiases: []
Q-omics provides the consensus-scored DGCR6 profile across patient tissues and cancer cell-line models. DGCR6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DGCR6 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DGCR6 RNA expression shows 15,476 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCEC, KIRC, and ESCA as cancer lineages where DGCR6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DGCR6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DGCR6 survival associations across molecular data types. DGCR6 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DGCR6 RNA expression–survival associations across cancer types. High DGCR6 expression shows unfavorable associations in UCEC and SKCM, but favorable associations in SCLC, KIRC, LGG and CESC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for DGCR6 RNA expression.
This table summarizes DGCR6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DGCR6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DGCR6 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, THCA, UCEC and COAD. The KIRC box plot shows higher DGCR6 RNA expression in tumor versus normal tissue (log2 FC = +0.870, t-test p < 0.001).
This table shows molecular features associated with DGCR6 in patient tissues and cancer cell lines. In patient samples, DGCR6 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, DGCR6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
